Dermata Therapeutics (DRMA) director gets 2,500 options with vesting

Rhea-AI Filing Summary

Dermata Therapeutics, Inc. director Kathleen D. Scott reported receiving a grant of stock options. The award covers 2,500 Stock Options (Right to Buy) Dermata common shares at an exercise price of $2.18 per share, with no cash paid at grant. These options were granted on 01/02/2026 and are held directly.

The options will vest in twelve equal monthly installments, with the first installment vesting one month after the grant date and additional portions vesting monthly thereafter, as long as Scott continues to serve the company through each vesting date. The options are scheduled to expire on 01/01/2036, and the filing shows 2,500 derivative securities beneficially owned following this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scott Kathleen D.

(Last) (First) (Middle)

3525 DEL MAR HEIGHTS RD., #322

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dermata Therapeutics, Inc. [ DRMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.18	01/02/2026		A		2,500		(1)	01/01/2036	Common Stock	2,500	$0	2,500	D

Explanation of Responses:

1. The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date.

	/s/ Gerald T. Proehl, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dermata Therapeutics (DRMA) report in this Form 4?

The filing shows that director Kathleen D. Scott received a grant of 2,500 Stock Options (Right to Buy) Dermata Therapeutics common stock on 01/02/2026, reported as a derivative security acquisition.

What is the exercise price of the stock options granted to Kathleen D. Scott at Dermata Therapeutics (DRMA)?

The Form 4 reports an exercise price of $2.18 per share for the 2,500 stock options granted to director Kathleen D. Scott.

How do the Dermata Therapeutics (DRMA) options granted to Kathleen D. Scott vest?

According to the footnote, the 2,500 options will vest in a series of twelve substantially equal monthly installments. The first installment vests on the one-month anniversary of the grant date, with additional installments vesting monthly thereafter, subject to her continuous service.

When do Kathleen D. Scotts Dermata Therapeutics (DRMA) stock options expire?

The Form 4 states that the stock options granted on 01/02/2026 are scheduled to expire on 01/01/2036, giving a long-term exercise window.

How many Dermata Therapeutics (DRMA) derivative securities does Kathleen D. Scott own after this transaction?

Following the reported grant, the filing lists 2,500 derivative securities (stock options) as beneficially owned by Kathleen D. Scott, held in direct ownership.

Is the Dermata Therapeutics (DRMA) Form 4 transaction a purchase of common stock or an option grant?

The transaction is reported as an option grant, specifically a Stock Option (Right to Buy) for 2,500 underlying shares, rather than a direct purchase or sale of common stock.